Baird Capital Portfolio Company NeuMoDx Receives FDA Emergency Use Authorization for SARS-CoV-2 Test

Baird Capital portfolio company NeuMoDx Molecular, which designs and develops molecular diagnostic solutions for hospital and clinical reference laboratories, today announced that the U.S. Food and Drug Administration (FDA) has issued an Emergency Use Authorization for a COVID-19 assay (test) for use on the company’s molecular systems.

The assay detects SARS-CoV-2, the virus that causes COVID-19, via nasopharyngeal, oropharyngeal and nasal swab specimens. NeuMoDx’s systems can provide test results in approximately 80 minutes.

For more information, see NeuMoDx’s press release.